Abstract: A phosphonium compound embedded in a matrix substrate wherein the phosphonium compound is selected from a group consisting of tris(hydroxyorgano)phosphine (THP), a THP+ salt (tetrakis(hydroxyorgano)phosphonium salt) or a condensate of THP and a nitrogen containing compound. The compound may be used to reduce the number of microorganisms in industrial systems and may also be used to reduce iron carbonate or iron, lead and zinc scale deposits.

Abstract: The present invention is related to pharmaceutical compositions that include a phosphonium antimicrobial agent. In a preferred embodiment, the present invention relates to an otic, nasal or ophthalmic composition (e.g., an aqueous ophthalmic solution) that includes a phosphonium salt compound as an antimicrobial agent. The compositions typically possess sufficient antimicrobial activity to satisfy USP preservative efficacy requirements and/or similar preservative standards (e.g., EP and JP).

Abstract: Fluorophosphate containing an ethylene-tetrafluoroethylene moiety of formula (I) or (II): (A)w-P(O)(O?M+)3-w??(I) or wherein A is Rf—(CH2)k—[(CF2CF2)y—(CH2CH2)z]mO and contains from about 8 to about 22 carbon atoms; Rf is CnF2n+1; n and k are each independently 1 to about 6; y, z, and m are each independently 1, 2, 3, or mixture thereof; w is 1 or 2 or a mixture thereof; and M is hydrogen, ammonium ion, an alkali metal ion, or an alkanolammonium ion, said fluorophosphate useful as a surfactant for altering the surface behavior of a liquid by addition thereto, and for providing surface effects to a substrate treated with a composition containing the fluorophosphate.

Abstract: A phosphocalcic compound modified by a gem-bisphosphonic acid or one of its salts, a method for preparing same, as well as its use for preparing an injectable composition. The modified phosphocalcic compound is obtained by adding a gem-bisphosphonic acid or one of its alkali metal or alkaline earth salts to a suspension of a precursor phosphocalcic compound in ultras-pure water, while stirring the reaction medium at room temperature, then in recovering by centrifuging the formed compound. The compound is useful for making an injectable composition, for use in the treatment of bone remodeling equilibrium.

Abstract: The invention relates to biology and medicine, in particular, can be used in medicine for preparation of a pharmaceutical composition for specific, self-regulating uncoupling of mitochondria. The invention may be useful in treatment of diseases and conditions associated with violation of cellular metabolism, in treatment of obesity including its pathological forms, as well as in treatment of diseases associated with increased formation of free radicals and reactive oxygen species. In addition, the invention may be used in biotechnology for stimulation of growth of yeast and microorganisms as well as for stimulation of development of tissues and organs of plant and animal origin.

Abstract: A phospholipid extract from a marine or aquatic biomass possesses therapeutic properties. The phospholipid extract comprises a variety of phospholipids, fatty acid, metals and a novel flavonoid.

Abstract: The present invention relates to compounds for the inhibition of pyruvate kinase and ATP production which are capable of inhibiting cancer cells proliferation.

Abstract: Novel wash and carrier solutions ideally suited for topical administration (e.g., as wash solutions and as carrier solutions). The solutions described herein are non-toxic, non-irritating, isotonic, possess non-specific broad-spectrum antimicrobial properties, and have an alkaline pH. Also disclosed are sterile preparations of the solutions and methods of using the same.

Abstract: The present invention is in the field of cholesterol and triglyceride-lowering methods and compositions. In particular, the present invention relates to the use of sphingolipids, more preferably phytosphingosine, sphingosine, sphinganine, ceramide, cerebroside and/or sphingomyelin for lowering the cholesterol and triglyceride levels in a subject and to the use of sphingolipids as a plasma and/or serum cholesterol and triglyceride lowering agent. The invention also encompasses methods of treatment of subjects suffering from high plasma cholesterol and triglyceride levels, as well as food items and supplements with increased sphingolipid levels.

Abstract: The present invention includes a method for delivering a medicament to a nail plate or nail bed that comprises providing a therapeutically effective amount of a medicament, etching the surface of the nail, and applying a medicament to the surface of the nail. A preferred embodiment of the present invention is directed to a method of treating a fungal infection of the fingernail or toenail. Also included in the present invention are the compositions (i.e., the etching compositions and/or the medicament compositions) used to treat the nail in accordance with the methods of the present invention.

Abstract: A pharmaceutical composition for therapeutic administration of pyrophosphate for phosphate repletion may be in either liquid or solid form and may be usable as or usable for preparing a hemodialysis or peritoneal dialysis solution containing a pyrophosphate compound present in an amount that provides a concentration in the dialysis solution equivalent to an inorganic phosphorus concentration of at least 0.5 mg per deciliter.

Abstract: A composition comprising a compound of formula (I) or (II): wherein r and q are independently integers of 1 to 3; Rf is linear or branched chain perfluoroalkyl group having 1 to 6 carbon atoms; j is an integer 0 or 1, or a mixture thereof, x is 1 or 2, Z is —O— or —S—, X is hydrogen or M, and M is an ammonium ion, an alkali metal ion, or an alkanolammonium ion is disclosed.

Abstract: The present invention relates to active compound combinations, in particular within a fungicide composition, which comprises (A) a thiazol-4-carbonic acid ester of formula (I) and a further fungicidally active compound (B). Moreover, the invention relates to a method for curatively or preventively controlling the phytopathogenic fungi of plants or crops, to the use of a combination according to the invention for the treatment of seed, to a method for protecting a seed and not at least to the treated seed.

Abstract: Active compound combinations are disclosed which comprise (A) a dithiino-tetracarboximide of formula (I) and a further insecticidally active compound (B). Methods for controlling animal pests such as insects and/or unwanted acarids and for curatively or preventively controlling the phytopathogenic fungi of plants or crops are also disclosed as well as the use of a composition according to the invention for the treatment of seed, to a method for protecting a seed and to the treated seed.

Abstract: A fosfomycin plus tobramycin combination formulation for delivery by aerosolization is described. The concentrated fosfomycin tobramycin combination formulation containing an efficacious amount of fosfomycin plus tobramycin is able to inhibit susceptible bacteria. Fosfomycin and tobramycin are formulated separately in a dual ampoule such that when reconstituted, the pH is between 4.5 and 8.0 or as a dry powder. The method for treatment of respiratory tract infections by a formulation delivered as an aerosol having a mass median aerodynamic diameter predominantly between 1 to 5?, produced by a jet or ultrasonic nebulizer (or equivalent) or dry powder inhaler.

Abstract: The present invention is a method for preventing or treating neuropathic pain. Using an agent to decrease the expression or activity of Toll-like receptor 4 (TLR4), behavioral hypersensitivity is attenuated thereby preventing or treating neuropathic pain in a subject in need of such treatment.

Abstract: Methods and compositions involving a class of boron-protected phenylphosphine agents having increased cell permeability and having improved chemical stability for treating or for preventing neuronal cell death-related diseases or conditions in a human or a non-human animal.

Abstract: The invention provides methods of preventing or treating a condition associated with DNA damage in an animal comprising the administration of a substance that interferes with the activity of the CUL4A ubiquitin ligase. The invention also provides a substance that interferes with the activity of CUL4A, as well as compositions comprising the interfering substance and a carrier. The substance of the invention preferably enhances nucleotide excision repair activity in an animal. The invention further provides methods of identifying substances that negatively or positively modulate the expression and/or activity of CUL4A.

Abstract: The present invention provides methods and compositions for the treatment of ion imbalances. In particular, the invention provides compositions comprising sodium-binding polymers and pharmaceutical compositions thereof. Methods of use of the polymeric and pharmaceutical compositions for therapeutic and/or prophylactic benefits are disclosed herein. Examples of these methods include the treatment of hypertension, chronic heart failure, end stage renal disease, liver cirrhosis, chronic renal insufficiency, fluid overload, or sodium overload.

Abstract: Solid and liquid pesticidal concentrate and spray compositions are described which exhibit enhanced efficacy due to the addition thereto of a compound which increases EPSPS enzyme inhibition by the pesticide, cell membrane permeability, or expression of hydroxyproline-rich glycoproteins.

Abstract: A method of treating a citrus plant is provided to reduce the incidence of one or more insect-vectored bacterial infections such as citrus greening. The method comprises the step of applying a treatment composition one or more times to the plant, wherein the treatment composition comprises an effective amount of aluminum tris(O-ethyl phosphonate).

Abstract: This invention relates to a method of treating myiasis of an animal by applying to the animal a composition comprising an parasiticidally effective amount of a compound of Formula 1, an N-oxide or a pharmaceutically or veterinarily acceptable salts salt thereof wherein R1 is Me, Cl, Br or F; R2 is F, Cl, Br, C1-C4 haloalkyl or C1-C4 haloalkoxy; R3 is F, Cl or Br; R4 is H; C1-C4 alkyl, C3-C4 alkenyl, C3-C4 alkynyl, C3-C5 cycloalkyl, or C4-C6 cycloalkylalkyl, each optionally substituted with one substituent selected from the group consisting of halogen, CN, SMe, S(O)Me, S(O)2Me, and OMe; R5 is H or Me; R6 is H, F or Cl; and R7 is H, F or Cl.

Abstract: There are described new active compound combinations of a compound of the formula (I) with known fungicidal active compounds, and their use for the control of phytopathogenic fungi.

Abstract: An exemplary method of treating a urologic symptom includes administering a daily dose of creatine to an individual wherein the daily dose of creatine lies in a range from about 0.35 mg to about 3.5 mg per kilogram body weight. Such an exemplary method may further include administering a dose of a compound that inhibits phosphodiesterase (e.g., at a time less than approximately 4 hours prior to sexual activity). Other exemplary methods, compounds, compositions, etc., are also disclosed.

Abstract: A method is provided for treatment of a condition including at least one weakened vertebra or one compression fracture of a vertebra, wherein in at least one embodiment, the vertebra is injected by vertebroplasty or kyphoplasty with particles, grains or granules or a mixture thereof, or an implant suspension including at least one resorbable fluid vehicle and particles, grains or granules or a mixture thereof, wherein the particles, grains or granules individually have a mean length from one side to the opposite side, through a geometrical centre, of up to 5 mm. Moreover, at least one embodiment of the present invention also provides use of the particular or granular material disclosed above, for the manufacture of a medicament for the vertebroplastic treatment or kyphoplastic treatment of a condition including at least one weakened vertebra or one compression fracture of a vertebra.

Abstract: According to the invention, wood material is treated with a composition comprising at least one C1-C7 monocarboxylic acid or a salt, or mixtures thereof, and at least one chelating agent. These compounds are dissolved in a liquid aqueous vehicle. In this manner, the treated wood is endowed with excellent resistance against detrimental environmental effects.

Abstract: A composition comprising at least a pyridylethylbenzamide derivative of general formula (I) (a) and a compound capable of inhibiting the transport of electrons of the respiratory chain in phytopathogenic fungal organisms (b) in an (a)/(b) weight ratio of from 0.01 to 20. A composition further comprising an additional fungicidal compound. A method for preventively or curatively combating the phytopathogenic fungi of crops by using this composition.

Abstract: A mixture for application on an animal to provide barrier protection against insects, parasites, arachnids and/or other arthropods, and ectoparasites, and in general viruses, bacteria and/or other microorganisms is provided. The mixture includes a carrier or combination of carriers, especially mineral oil, that at least after application has an absolute or resultant viscosity of from 100 to 1200, and especially greater than 120, and especially 300 to 650 S.U.S. The mixture also includes an insecticide, ectoparasitide, insect or other arthropod growth regulator (IGR), viricide, bacteriacide and/or bacteriostatic compound that is blended with the carrier and that acts non-systemically. The mixture contains essentially no surfactant, emulsifier, or emulsifying agent, either in solution or suspension.

Abstract: A nucleic acid sequence encoding Mammastatin, a specific mammary cell growth inhibitor. Mammastatin is encoded by a single nucleic acid sequence and has an approximate molecular weight of 44 kDa in its inactive, non-phosphorylated form. Normal mammary cells express functional phosphorylated forms having approximate molecular weights of 53 kDa and 49 kDa. Metastatic mammary cells either do not express Mammastatin at all, or do not express the 53 kDa or 49 kDa, phosphorylated forms. Mammary cancer cells are inhibited in their growth by the administration of phosphorylated mammastatin.

Abstract: Conventional many fungicidal compositions have had practical problems such that either a preventive effect or a curing effect is inadequate, the residual effect tends to be inadequate, or the controlling effect against plant diseases tends to be inadequate depending upon the application site, and a fungicidal composition to overcome such problems has been desired.

Abstract: A biodelivery system has been found which increases the efficiency and effectiveness of introducing antimicrobial compounds into complex biofilm matrices through the use of liposome carriers, thereby removing the biofouling in industrial water bearing systems, including piping, heat exchanges, condensers, filtration systems and fluid storage tanks. According to one embodiment of the invention, antimicrobial containing liposomes are added to water systems prone to biofouling and biofilm formation. The liposomes, being similar in composition to microbial membranes or cells, are readily incorporated into the existing biofilm. Once the antimicrobial compound containing liposomes become entrained within the biofilm matrix, the decomposition or disintegration of the liposome proceeds. Thereafter the biocidal core is released to react directly with the biofilm encased microorganisms.

Abstract: The present invention relates to a protein/phospholipid or protein hydrolyzate/phospholipid complex containing 10 wt % or more of bound phospholipid, a lipid metabolism improving agent comprising the complex, and a functional food comprising the complex. The present invention provides a lipid metabolism improving agent and a functional food, containing the complex.

Abstract: Embodiments of the present invention relate to insecticidal Bacillus thuringiensis Cry1 and Cry2 polypeptides. Methods for using the polypeptides and nucleic acids of embodiments of the invention to synergistically enhance resistance of plants to insect predation are encompassed in embodiments of the present invention.

Abstract: Devices are provided which are functionalized to include surface regions having anti-infective agents. Methods are provided for functionalizing various material surfaces to include active surface regions for binding anti-infective agents. Methods are provided by which anti-infective moieties or agents are bonded to functionalized surfaces.

Abstract: The present invention relates to a metal triangulo compound. Provided is also a method of inducing apoptosis in a cell that comprises administering the metal triangulo compound. Provided is also a method of preventing carcinogenesis in a cell that comprises administering the metal triangulo compound.

Abstract: This invention provides a method of treating pain in a mammal that includes administering to a mammal in need of such treatment a pain treating effective amount of a compound of the formula (I): where R1 is H, alkyl or phenylalkyl; R2 is H, alkyl, alkenyl or phenylalkyl; or R1 and R2 taken together as Z are —CH2C—H2—, —CH2C(R6)(R7)CH2— or —CH2C(R8)(R9)—C(R10)(R11)CH2—, where R6, R8 and R10 are, independently, H, alkyl or hydroxyl and R7, R9 and R11 are, independently, H or alkyl; A is alkylene or alkenylene; X is CO2R3, P(O)(OR4)(OR5), 3,5-dioxo-1,2,4-oxadiazolidin-2-yl or 5-tetrazolyl in which R3, R4 and R5 are, independently, H or alkyl, or a pharmaceutically acceptable salt thereof. The present invention also provides pharmaceutical compositions for treating pain containing a pain treating effective amount of the compound of formula (I).

Abstract: A shelf-stable consumable composition may comprise one or more Probiotic-Mimicking Elements (PMEs) wherein the median particle size of the one or more PMEs is less than the median particle size of a probiotic from which the one or more PMEs were derived. In some embodiments, the median particle size of the one or more PMEs may be less than about 0.2 microns. In some embodiments, the PMEs may comprise at least one of peptides, fatty acids, bacteriocins, cell surface proteins, phospholipids, teichoic acids, and nucleic acids, and may be combined with one or more prebiotics, such as oligosaccharides, inulin, short-chain fructo-oligosaccharides, xylooligosaccharides, galactooligosaccharides, soyoligosaccharides, and lactulose/lactitol. Methods for preparing and using a shelf-stable consumable composition for promoting digestive health in a subject are also described.

Abstract: The present invention relates to novel pyridazine derivatives of formula (I) as active ingredients which have microbiocidal activity, in particular fungicidal activity: wherein R1 is hydrogen, C1-C6alkyl, C1-C8haloalkyl or C3-C6cycloalkyl; R2 is cycloalkyl, cycloalkylalkyl, halocycloalkyl, cycloalkoxy, halocycloalkoxy, cycloalkylalkoxy, halocycloalkylalkoxy, alkoxyalkyl, cycloalkoxyalkoxyalkyl, haloalkoxyalkyl, trialkylsilyl, alkylthioalkyl, haloalkylthioalkyl, cycloalkylthio, halocycloalkylthio, cycloalkylalkylthio, halocycloalkylalkylthio, alkylsulfinylalkyl, alkylsulfonylalkyl, alkylsulfinyl, haloalkylsulfinyl, alkylsulfonyl, haloalkylsulfonyl, C2-C6alkenyl, C2-C6alkynyl, optionally substituted arylsulfonyl, optionally substituted aryloxy, optionally optionally substituted heteroaryloxy, optionally substituted arylthio, optionally substituted heteroarylthio; or R2 together with an adjacent carbon atom forms an optionally substituted fused ring; R3 is an optionally substituted aryl; R4 is hydrogen, halogen,

Abstract: The present invention relates generally to pharmacological methods for the prevention or amelioration of sleep-related breathing disorders via administration of cannabimimetic agents and combinations thereof.

Abstract: This invention relates to novel colonic purgative compositions in a solid dosage form, comprising at least one purgative and at least one soluble, or soluble, nonfermentable binder, such as polyethylene glycol. Further, this invention relates to methods of using the colonic purgative compositions. The present compositions and methods are designed to improve patient tolerance and compliance, while at the same time improving the quality of bowel cleansing. The formulations and methods of this invention are particularly useful to cleanse the bowel prior to diagnostic and surgical procedures and can also be employed in lower dosages as a laxative to promote elimination and/or to relieve constipation.

Abstract: Compositions and methods for enhancing paracellular permeability at an absorption site in a subject are disclosed. The method includes: (a) administering an effective amount of a phospholipase C inhibitor to a subject at a time in which enhanced paracellular permeability is desired; and (b) enhancing paracellular permeability in the subject at the absorption site through the administering of the effective amount of the phospholipase C inhibitor. The disclosed compositions and methods provide enhanced absorption of a hydrophilic drug in a subject.

Abstract: The present invention relates to new dimethylphenoxy inhibitors of viral protease or parasitic enzymes, pharmaceutical compositions thereof, and methods of use thereof.

Abstract: In order to form liposomes with a longer half-life in blood, use is made of defined compounds with the general formula (A)

Abstract: Chronic alcoholism is a diverse and heterogeneous disorder that can be dichotomized into cognitively intact and cognitively impaired subgroups. At a molecular level, ethanol has been shown to have both acute and chronic effects on: Membrane biophysical properties, Membrane composition and metabolism, Protein phosphorylation, Lipid metabolic signaling, Lipoprotein transport of cholesterol. Actual molecular underpinnings are determined for cognitive impairment seen in some chronic alcoholism subjects including molecular/metabolic alterations of phospholipid and ganglioside metabolisms.

Abstract: This invention relates to novel colonic purgative compositions in a solid dosage form, comprising at least one purgative and at least one soluble, or soluble, nonfermentable binder, such as polyethylene glycol. Further, this invention relates to methods of using the colonic purgative compositions. The present compositions and methods are designed to improve patient tolerance and compliance, while at the same time improving the quality of bowel cleansing. The formulations and methods of this invention are particularly useful to cleanse the bowel prior to diagnostic and surgical procedures and can also be employed in lower dosages as a laxative to promote elimination and/or to relieve constipation.

Abstract: Membrane permeable prodrugs of creatine phosphate analogs, pharmaceutical compositions comprising membrane permeable prodrugs of creatine phosphate analogs, and methods of treating diseases such as ischemia, heart failure, and neurodegenerative disorders comprising administering prodrugs of creatine phosphate analogs, or pharmaceutical compositions thereof are disclosed.

Abstract: A method of and kit for diagnosing cardiovascular disease in a human involves assessing the presence and/or concentration of antibodies to platelet activating factor (PAF) in a sample of body fluid of the human.

Abstract: The present invention relates to a pesticide composition intended for protecting plants, crops or seeds against phyto-pathogenic fungi or damaging insects, and the corresponding methods of treatment using the said composition. More precisely, the subject of the present invention is a pesticide composition based on fosetyl-Al, propamocarb-HCl, an insecticide active substance and optionally a further fungicide active substance.

Abstract: Glycerophosphate salts have been found to mitigate the syndromes or conditions of discomfort associated with hem-orrhagic cystitis. Therefore, methods are provided for treating or preventing the syndromes or conditions of discomfort associated with hemorrhagic cystitis using a glycerophosphate salt, hi particular, methods are provided for treating or preventing the syndromes or conditions of discomfort associated with hemorrhagic cystitis using calcium glycerophosphate (CGP).

Abstract: The present invention provides an external preparation for skin comprising a phospholipid having an iodine value of 80 to 110, ethanol in an amount of 55 to 83 wt % and water in an amount of 15 to 43 wt %, which is improved in it's preparation stability by suppressing an increase in an acid value of phospholipid. The present invention also provides an external preparation for skin which is improved in percutaneous absorption of medically effective ingredient(s). The present invention provides further a method for suppressing an increase in an acid value of phospholipid by comprising phospholipid having high iodine value and high concentration of ethanol and water, as well as a method for improving percutaneous absorption of medically effective ingredient(s) in external preparation for skin.